## Alessandra Malaroda

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8199289/publications.pdf

Version: 2024-02-01

9 235 7 8 papers citations h-index g-index

9 9 9 9 362

times ranked

citing authors

docs citations

all docs

#	Article	IF	CITATIONS
1	A Phase I Trial of Radioimmunotherapy with 131I-A5B7 Anti-CEA Antibody in Combination with Combretastatin-A4-Phosphate in Advanced Gastrointestinal Carcinomas. Clinical Cancer Research, 2009, 15, 4484-4492.	7.0	68
2	OpenDose: Open-Access Resource for Nuclear Medicine Dosimetry. Journal of Nuclear Medicine, 2020, 61, 1514-1519.	5.0	54
3	A Phase I Clinical Trial of CHT-25 a 131I-Labeled Chimeric Anti-CD25 Antibody Showing Efficacy in Patients with Refractory Lymphoma. Clinical Cancer Research, 2009, 15, 7701-7710.	7.0	40
4	The Use of BED And EUD Concepts in Heterogeneous Radioactivity Distributions on a Multicellular Scale for Targeted Radionuclide Therapy. Cancer Biotherapy and Radiopharmaceuticals, 2007, 22, 143-150.	1.0	25
5	Investigation of the radiation dose from coneâ€beam <scp>CT</scp> for imageâ€guided radiotherapy: A comparison of methodologies. Journal of Applied Clinical Medical Physics, 2018, 19, 174-183.	1.9	21
6	Systematic investigation on the validity of partition model dosimetry for 90Y radioembolization using Monte Carlo simulation. Physics in Medicine and Biology, 2017, 62, 7342-7356.	3.0	10
7	The Application of Dose-Rate Volume Histograms and Survival Fractions to Multicellular Dosimetry. Cancer Biotherapy and Radiopharmaceuticals, 2005, 20, 58-65.	1.0	9
8	64Cu-SAR-Bombesin PET-CT Imaging in the Staging of Estrogen/Progesterone Receptor Positive, HER2 Negative Metastatic Breast Cancer Patients: Safety, Dosimetry and Feasibility in a Phase I Trial. Pharmaceuticals, 2022, 15, 772.	3.8	8
9	3D probability driven random walk segmentation with automated seed selection for the delineation of PET volumes. , $2018,  ,  .$		O